Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.99% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Jun 30, 2023
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-23-000015General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-18.51% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
41.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
31.51% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
76.37% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-72.10% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
77.97% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
23.78% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 4.35%
- Current
- 4.99%
- Delta
- 0.64%
- Previous
- -52.14%
- Current
- -18.51%
- Delta
- 33.63%
- Previous
- 49.72%
- Current
- 41.78%
- Delta
- -7.94%
- Previous
- 41.30%
- Current
- 31.51%
- Delta
- -9.79%
- Previous
- 87.02%
- Current
- 76.37%
- Delta
- -10.66%
- Previous
- -46.92%
- Current
- -72.10%
- Delta
- -25.18%
- Previous
- 72.21%
- Current
- 77.97%
- Delta
- 5.75%
- Previous
- 12.51%
- Current
- 23.78%
- Delta
- 11.27%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Analogous To · ALNY state analogue 5 →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_DECREASED →Transitioned To · ALNY R_AND_D_INTENSITY_INCREASED →Transitioned To · ALNY SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.